• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Experimental study to develop Src-targeted molecular therapy in small cell lung cancer

Research Project

Project/Area Number 22501044
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Clinical oncology
Research InstitutionTottori University

Principal Investigator

IGISHI Tadashi  鳥取大学, 医学部, 准教授 (80273895)

Co-Investigator(Kenkyū-buntansha) MATSUMOT Shingo  独立行政法人国立がん研究センター, 臨床開発センター, 研究員 (10392341)
HASHIMOTO Kiyoshi  鳥取大学, 医学部附属病院, 助教 (50379640)
Project Period (FY) 2010 – 2012
Project Status Completed (Fiscal Year 2012)
Budget Amount *help
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Keywords小細胞肺癌 / 分子標的治療 / Src
Research Abstract

Stem cell factor/c-kit and insulin-like growth factor-I(IGF-I)/IGF-I receptor were detected in small cell lung cancer specimens. In small cell lung cancer cell line, H209 cells, both stem cell factor and IGF-I induced amrubicin resistance. A Src inhibitor, dasatinib, restored the sensitivity to amrubicinin stem cell factor-treated H209 cells. However, dasatinib did not affected IGF-I-induced amrubicinresistance.

Report

(4 results)
  • 2012 Annual Research Report   Final Research Report ( PDF )
  • 2011 Annual Research Report
  • 2010 Annual Research Report

URL: 

Published: 2010-08-23   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi